ClinicalTrials.gg
CompletedNCT03961919FLAT-AutoUpdated Nov 18, 2023

Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant

A Phase 2 interventional study of Fludarabine and ARA-C in Acute Myeloid Leukemia, Myelodysplastic Syndromes and Transplant-Related Hematologic Malignancy, sponsored by Ciceri Fabio. Completed at 1 site in Italy. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Ciceri Fabio · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 10 years 3 months after the study started (first participant enrolled Feb 2009, registered May 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing treosulfan in Leukemia, Myeloid, Acute — 4 open to participants now, 5 under way, none of them phase 3. treosulfan · Leukemia, Myeloid, Acute.

Enrollment
14th of 14
15 · median 68
Started
2009
with 1 other
Phase 2
11 of 14
4 open now
Registered
7th of 14
by date
Lead sponsor
1 of 14
Ciceri Fabio

Among the 14 studies testing treosulfan in Leukemia, Myeloid, Acute, this one is the 14th largest by enrollment, is one of 2 that started in 2009, is one of 11 in phase 2, and was the 7th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

4 of the 14 studies testing treosulfan in Leukemia, Myeloid, Acute are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About treosulfan

treosulfan: first FDA approval 2025 (GRAFAPEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing treosulfan in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

FLAT-Auto is a phase II trial. fludarabine and ARA-C will be combined with the alkylating agent treosulfan (FLAT), to investigate the feasibility and the efficacy of a new regimen, supported with autologous peripheral blood SCT (PBSCT), as final postremission consolidation in AML/MDS elderly patients.

03

Conditions studied

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • Transplant-Related Hematologic Malignancy
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pts with de novo or secondary AML or with Int 2 or High risk MDS according to IPSS.
  • Pts unable or unfit to receive SCT from an HLA (human leukocyte antigen)-identical related (SIB) or unrelated (MUD), or HLA-haploidentical related (HAPLO) donor.
  • Hematologic CR (Appendix D) after 1 or 2 cycles of induction standard chemotherapy.
  • Successful collection of autologous PBSC: ≥ 5.0x10e6 /kg patient bodyweight (BW)
  • Age ≥ 65 years.
  • Performance status 0-2 (Eastern Cooperative Oncology Group), 60-100% (Appendix E).
  • Written .

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of AML M3.
  • Second concomitant .
  • Severe concomitant illnesses/medical conditions (e.g. impaired respiratory and/or cardiac function).
  • Known and manifested malignant involvement of the central nervous system (CNS)
  • Active infectious disease
  • - positivity or active hepatitis infection
  • Impaired liver function ( > 1.5 x upper normal limit; transaminases > 3.0 x upper normal limit)
  • Impaired renal function (creatinine-clearance \< 60 ml/min; serum creatinine > 1.5 x upper normal limit).
  • Known to treosulfan and/or cytarabine and/or fludarabine
  • Participation in another experimental drug trial within 4 weeks before day -6
  • Non-cooperative behaviour or non-compliance
  • Psychiatric diseases or conditions that might impair the ability to give
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    FLAT-Auto

    Treosulfan in a combination regimen with ARA-C and fludarabine as conditioning therapy prior to autologous PBSCT

    Drug: Fludarabine · Drug: ARA-C · Drug: Treosulfan · Procedure: Peripheral Blood Stem Cell Transplant

Interventions

  • Fludarabine i.v. 30 mg/m²/d day -6 to -2

  • DrugCytarabineStudies of CytarabineCytarabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cytarabine i.v. 2 g/m²/d day -6 to -2

  • Treosulfan i.v. 10 g/m²/d day -6 to -4

  • ProcedurePeripheral Blood Stem Cell Transplant

    Autologous stem-cell transplantation i.v.: day 0 (source: peripheral blood) Pegylated-Filgrastim s.c. 6 mg day +3

06

What researchers measure

Primary outcomes

  1. Evaluation of disease free survival from first Complete Remission (CR)

    Evaluation of disease-free survival (DFS) duration from documented first CR of AML or MDS with intermediate 2 or high IPSS (International Prognostic Score System).

    Time frame: 2 years after transplantation

07

Study locations

1 site
  • Ospedale San Raffaele
    Milano, Lombardia 20132, Italy
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2009 to primary completion in Dec 2019, 130 months.

Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's 130 months is above that.

Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2019
First posted
May 23, 2019
StartActual
Feb 10, 2009
Primary completionActual
Dec 31, 2019
CompletionActual
Dec 31, 2021
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03961919
Lead sponsor
Ciceri Fabio
Responsible party
Ciceri Fabio (Head of Hematology and Translplant Unit, IRCCS San Raffaele) — Sponsor-investigator
First posted
May 23, 2019
Start date
Feb 10, 2009
Primary completion
Dec 31, 2019
Completion
Dec 31, 2021
Last update
Nov 18, 2023

Study contacts

Fabio Ciceri, MD
principal investigator · San Raffaele Hospital IRCCS

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treosulfan

Start the discussion